Is Triple Therapy Better for Kidney Cancer? LITESPARK-012 Results

Short answer: In LITESPARK-012, adding belzutifan or quavonlimab to first-line pembrolizumab and lenvatinib did not demonstrate a significant improvement in progression-free or overall survival in advanced clear-cell kidney cancer. Adverse events led to discontinuation of at least one drug more frequently with the investigational triplets. The findings do not support routine use of these two combinations. [1, 3, 5]

Combining medicines that act through different pathways is an important strategy in cancer research. However, activity in another setting does not guarantee additional benefit when a drug is added to an established regimen. LITESPARK-012 tested this directly against an active two-drug treatment. [2, 3]

Which patients were included?

The study involved patients with advanced clear-cell renal cell carcinoma who had not previously received systemic therapy for advanced disease. “Clear-cell” describes the pathological subtype. “First-line” refers to the initial systemic treatment for advanced cancer; it does not necessarily mean that the patient has never undergone kidney surgery. [2, 5]

This distinction matters. Surgery for a localized kidney tumour, treatment intended to reduce recurrence after surgery and systemic therapy for advanced disease address different clinical situations. The findings should not be applied automatically to every kidney cancer diagnosis.

Why was a third drug added?

Pembrolizumab targets the PD-1 immune checkpoint, while lenvatinib inhibits several tyrosine kinases involved in tumour growth and blood-vessel formation. Belzutifan inhibits HIF-2α. Quavonlimab is an investigational antibody targeting CTLA-4, another immune checkpoint. [2, 3]

The rationale was to improve disease control by acting on additional pathways. Whether this translates into clinical benefit must be assessed alongside survival, adverse events and the ability to continue treatment.

How was LITESPARK-012 designed?

The randomized, open-label phase 3 trial assigned 1,688 patients to three groups: 560 received an assignment to pembrolizumab + lenvatinib + belzutifan, 562 to MK-1308A + lenvatinib, and 566 to the control regimen of pembrolizumab + lenvatinib. [3, 5]

MK-1308A is a coformulation of pembrolizumab and quavonlimab, so this treatment also contains three active agents. The dual primary endpoints were progression-free survival assessed by blinded independent central review and overall survival. [2, 3, 5]

In an open-label trial, patients and clinicians know the assigned treatment. Blinded central assessment of imaging helps reduce potential assessment bias for the progression endpoint.

What happened to progression-free survival?

At a median follow-up of 43.6 months, the following results were reported. [5]

Source: LITESPARK-012 congress results. Efficacy results concern all randomized patients; discontinuation rates concern the treated safety population. [5]

Progression-free survival measures the time until cancer progression or death. It is different from overall survival. A median also cannot predict precisely how long an individual patient will benefit.

The numerically shorter medians in the triplet groups do not, on their own, establish statistical superiority of the doublet. The central conclusion is that adding a third drug did not demonstrate superiority.

How should overall survival and statistical testing be interpreted?

Neither investigational regimen demonstrated a significant overall survival improvement. It would therefore be inaccurate to say that either triplet prolonged life. Failure to demonstrate superiority also does not prove that the treatments are equivalent. [3, 5]

For the quavonlimab comparison, the prespecified testing sequence began with patients in the IMDC intermediate- and poor-risk groups. Superiority was not established there, so results for all randomized patients should not be given the same confirmatory statistical interpretation. The 20.7- and 23.7-month figures above describe the overall randomized population. [5]

Why does treatment discontinuation matter?

Adverse events led to discontinuation of at least one study drug in approximately half of patients receiving a triplet, compared with about one-third receiving the doublet. An adverse event is a medical occurrence during treatment; it is not necessarily proven to have been caused by the medicine. [5]

These percentages do not mean that all treatment components were stopped, nor do they represent the overall frequency of adverse events. More frequent discontinuation may have reduced treatment exposure, but this should not be described as the proven sole explanation for the efficacy findings.

Can belzutifan still be used in other settings?

Yes. LITESPARK-012 evaluated adding belzutifan to pembrolizumab and lenvatinib as first-line treatment. Other belzutifan strategies involve different patient populations and separate evidence.

For example, on September 24, 2026, the FDA approved belzutifan with lenvatinib for certain adults with advanced kidney cancer after a PD-1 or PD-L1 inhibitor. That decision was based on LITESPARK-011. It is not approval of the first-line triplet examined here. [4]

Editorial assessment

LITESPARK-012 provides a large randomized test of whether treatment intensification improves outcomes. Its findings illustrate why adding medicines requires clinical evidence, even when the biological rationale is plausible.

Pembrolizumab and lenvatinib remains a first-line option for suitable patients. This trial does not establish that it is superior to every other first-line regimen. Treatment selection still requires consideration of the cancer, previous therapy, other illnesses, expected toxicity and patient priorities.

Frequently asked questions

Does this mean all kidney cancer triplets are ineffective?

No. The findings concern the two combinations and patient population studied.

Does a median progression-free survival of 20.8 months predict life expectancy?

No. It is a study-level measure of time to progression or death, not an individual survival prediction.

Should someone already receiving belzutifan stop treatment?

This study alone does not justify stopping it. The treatment setting and reason for prescribing it may differ from LITESPARK-012.

Sources

1. Rini BI, Choueiri TK, Voss MH, Burotto M. Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study. Annals of Oncology. 2026. doi:10.1016/j.annonc.2026.10.1281
2. Choueiri TK, Powles T, Voss MH, Plimack ER. LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. Future Oncology. 2023;19(40):2631–2640. doi:10.2217/fon-2023-0283 · PubMed
3. Merck–Eisai. Update on the phase 3 LITESPARK-012 trial evaluating first-line combination treatments for advanced renal cell carcinoma, April 21, 2026 [Internet]. Available from: https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-litespark-012-trial-evaluating-first-line-combination-treatments-for-certain-patients-with-advanced-renal-cell-carcinoma-rcc/
4. U.S. Food and Drug Administration. FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component, September 24, 2026 [Internet]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-combination-lenvatinib-advanced-renal-cell-carcinoma-clear-cell-component
5. KOL Pulse. LITESPARK-012: No PFS or OS Gain With Triplets in 1L RCC — ESMO 2026. Secondary source containing presentation slides and detailed results [Internet]. Available from: https://kolpulse.com/kol-pulse-trial-profile-litespark-012